Product Description
a Kv7 channel opener; Mechanistic studies showed PF-04895162 had low cytotoxic potential in human hepatocytes, but inhibited liver mitochondrial function and bile salt export protein (BSEP) transport. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30784208/)
Mechanisms of Action: Potassium Channel Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Epilepsy
Phase 1: Hyperalgesia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ICA-105665-04 | P2 |
Terminated |
Epilepsy |
2010-09-01 |
|
ICA-105665-05 | P1 |
Completed |
Hyperalgesia |
2009-12-01 |